| 肿瘤治疗的新途径：嵌合抗原受体T细胞疗法 |
| |
| 引用本文： | 黄彦杰 徐睿. 肿瘤治疗的新途径：嵌合抗原受体T细胞疗法[J]. 国际生物制品学杂志, 2018, 41(4): 190-194. DOI: 10.3760/cma.j.issn.1673-4211.2018.04.008 |
| |
| 作者姓名： | 黄彦杰 徐睿 |
| |
| 作者单位： | 200051 上海生物制品研究所有限责任公司第一研究室 |
| |
| 摘 要： | 免疫疗法已经成为癌症治疗中的重要手段。使用嵌合抗原受体（chimeric antigen receptor，CAR）修饰的T细胞治疗癌症因其显著的疗效成为了癌症治疗研究的新方向。CAR包含抗原结合部分、铰链区、跨膜结构域以及结合活化T细胞的细胞共刺激结构。对目标肿瘤的特异性清除是通过CAR-T细胞对抗原的特异性选择和共刺激信号转导，CAR-T细胞在过继后的转运、维持，以及抗肿瘤功能的保留实现的。此文对目前基于CAR-T细胞疗法的基本原理及临床应用作一阐述。
|
| 关 键 词： | 癌症 嵌合抗原受体 T细胞；免疫疗法 临床研究 |
New pathway in cancer therapy: chimeric antigen receptor-T cell therapy |
| |
| Affiliation: | First Research Laboratory, Shanghai Institute of Biological Products Co., Ltd., 200051 Shanghai, China |
| |
| Abstract: | Immunotherapy has become an important way in cancer treatment. Using chimeric antigen receptor (CAR) -modified T cells in cancer treatment has become a new therapeutic approach for cancer because of its significant effect. CAR comprises an antigen-binding moiety, a hinge region, a transmembrane domain, and a cell costimulatory structure that binds to T cell leading to its activation. The specific clearance of the targeted tumor is achieved by the specific selection of antigen and, co-stimulatory signal transduction through CAR- T cells, the transpart and maintenance of CAR-T cells after inheritance, as well as retention of antitumor functions. This review addresses the current clinical and preclinical studies based on CAR-T cell therapy. |
| |
| Keywords: | Cancer Chimeric antigen receptor T cell Immunotherapy Clinical study |
|
| 点击此处可从《国际生物制品学杂志》浏览原始摘要信息 |
|
点击此处可从《国际生物制品学杂志》下载免费的PDF全文 |
